The Top 25 Comorbidities Reported During Inpatient Stays for Pediatric Hematopoietic Stem Cell Transplant: Patient Demographics and Impact on Inpatient Mortality and Charges

Persistent Link:
http://hdl.handle.net/10150/614607
Title:
The Top 25 Comorbidities Reported During Inpatient Stays for Pediatric Hematopoietic Stem Cell Transplant: Patient Demographics and Impact on Inpatient Mortality and Charges
Author:
Zulueta, Stacy; Clemans, Emily; Skrepnek, Grant
Affiliation:
College of Pharmacy, The University of Arizona
Issue Date:
2011
Rights:
Copyright © is held by the author.
Collection Information:
This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.
Publisher:
The University of Arizona.
Abstract:
OBJECTIVES: The purpose of this study was to analyze the impact of patient and hospital characteristics as well as selected comorbidities on inpatient mortality and charges in pediatric HSCT. We have determined the top 25 comorbidities reported during all inpatient stays for HSCT as well as for those stays ending in mortality. METHODS: All data was extracted from the AHRQ KID databases for the years 1997, 2000, 2003, and 2006. Two regression analyses were performed to determine the contribution of various independent variables on mortality and charges. Subjects of this study included all cases of HSCT reported in the Healthcare Cost and Utilization Project (HCUP) KID as ICD-9 41.XX. RESULTS: Factors accounting for larger increases in cost included death during hospital stay, the development of disseminated intravascular coagulation (DIC), pneumonia, and length of stay (LOS). The largest decreases in charges were seen for patients coming from a small or “micropolitan” location, patients cared for in teaching hospitals, and in hospitals with large bedsizes. Variables associated with increased risk of mortality on linear regression included development of DIC, sepsis, or pneumonia. CONCLUSION: Further study relating to HSCT is necessary to determine the contribution of specific comorbidities to mortality and charges. Importantly, DIC is associated with both greater risk of mortality and greater charges. It would be prudent to recommend increased monitoring and early treatment for DIC based on these results.
Description:
Class of 2011 Abstract
Keywords:
comorbidities; hematopoietic stem cell transplant; pediatric; mortality; Healthcare Cost and Utilization Project (HCUP)
Advisor:
Skrepnek, Grant

Full metadata record

DC FieldValue Language
dc.contributor.advisorSkrepnek, Granten
dc.contributor.authorZulueta, Stacyen
dc.contributor.authorClemans, Emilyen
dc.contributor.authorSkrepnek, Granten
dc.date.accessioned2016-06-24T15:45:57Z-
dc.date.available2016-06-24T15:45:57Z-
dc.date.issued2011-
dc.identifier.urihttp://hdl.handle.net/10150/614607-
dc.descriptionClass of 2011 Abstracten
dc.description.abstractOBJECTIVES: The purpose of this study was to analyze the impact of patient and hospital characteristics as well as selected comorbidities on inpatient mortality and charges in pediatric HSCT. We have determined the top 25 comorbidities reported during all inpatient stays for HSCT as well as for those stays ending in mortality. METHODS: All data was extracted from the AHRQ KID databases for the years 1997, 2000, 2003, and 2006. Two regression analyses were performed to determine the contribution of various independent variables on mortality and charges. Subjects of this study included all cases of HSCT reported in the Healthcare Cost and Utilization Project (HCUP) KID as ICD-9 41.XX. RESULTS: Factors accounting for larger increases in cost included death during hospital stay, the development of disseminated intravascular coagulation (DIC), pneumonia, and length of stay (LOS). The largest decreases in charges were seen for patients coming from a small or “micropolitan” location, patients cared for in teaching hospitals, and in hospitals with large bedsizes. Variables associated with increased risk of mortality on linear regression included development of DIC, sepsis, or pneumonia. CONCLUSION: Further study relating to HSCT is necessary to determine the contribution of specific comorbidities to mortality and charges. Importantly, DIC is associated with both greater risk of mortality and greater charges. It would be prudent to recommend increased monitoring and early treatment for DIC based on these results.en
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectcomorbiditiesen
dc.subjecthematopoietic stem cell transplanten
dc.subjectpediatricen
dc.subjectmortalityen
dc.subjectHealthcare Cost and Utilization Project (HCUP)en
dc.titleThe Top 25 Comorbidities Reported During Inpatient Stays for Pediatric Hematopoietic Stem Cell Transplant: Patient Demographics and Impact on Inpatient Mortality and Chargesen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.